Solvay Pharmaceuticals, Gmbh

Abbott Products Gmbh

Jochen Antel

Holger Sann

Samuel David

Ulf Preuschoff

Harald Waldeck

Reinhard Brueckner

Michael Wurl

Peter-Colin Gregory

Dania B Reiche

Michael Firnges

Uwe Schoen

Daniel Jasserand

Michael Weske

Christian Eeckhout

Johannes Hebebrand

Gerhard-Wilhelm Bielenberg

Timo Heinrich

Dieter Ziegler

Josephus Hubertus Maria Lange

Peter Eickelmann

Wolfgang Kehrbach

Josef Messinger

Dagmar Hoeltje

Dirk Thormaehlen

Bernd Junker

Claudia Berger

Peter Colin Gregory

Andreas Potthoff

Reinhard Brückner

Sabine Eyting

Maike Wolff

Sabine Irmer

Michael Reggelin

Horst Kessler

Dirk Weber

Michael Peck

Uwe Reinecker

Jan H Van Maarseveen

Jack A Den Hartog

Chris G Kruse

Jan-Hendrik Reinders

Dania Reiche

Described is a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at least one Kchannel opener as a first active agent and at least one CBcannabinoid receptor antagonist as a second active agent. The invention is further directed to such novel combination therapy wherein a dually acting compound with combined Kchannel opening and CBantagonistic properties is used. The invention also relates to novel pharmaceutical compositions comprising Kchannel openers and CBantagonists and the use of said pharmaceutical compositions in the treatment, delayed progression, delayed onset of and/or inhibition of diabetes mellitus type 1, and the prophylaxis and treatment, of obesity as well as the prophylaxis, treatment, delayed onset and/or inhbition of its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, in mammals and humans. The invention is further directed to such novel pharmaceutical compositions comprising a dually acting compound with combined Kchannel opening and CBantagonistic properties.

Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions

The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and related or other conditions. 

N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions

4-substituted 1-amidomethylcarbonyl-piperidine compounds having motilin-agonistic properties and their acid addition salts, pharmaceutical compositions containing these compounds, processes and intermediate products for the preparation of these compounds, and methods of treatment utilizing these compounds.

1-amidomethylcarbonyl-piperidine compounds, methods and intermediate products for the production thereof and pharmaceutical formulations containing said compounds

Described herein are pharmaceutical compositions comprising therapeutically effective quantities of (i) a Kchannel modulator; and (ii) a CBmodulator. Also described herein are methods of making and using these compositions.

Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators

3-cyanonaphthalene-1-carboxylic acid perhydroxyalkylmethyl-piperazine compounds of formula I which are antagonistic to tachykinin receptors, pharmaceutical compositions containing such compounds, methods of using such compounds for the treatment and/or inhibition of various diseases and disorders, processes for preparing such piperazine compounds, and intermediate products of these processes.

NK1 and NK2-antagonists and compositions and methods of using the same

N-sulfamoyl-N'-benzopyranpiperidine compounds of formula I and their physiologically acceptable acid addition salts, pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and related concomitant and/or secondary diseases or conditions 

N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof

A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.

Method of preparing pharmaceutical compositions

Selectively BRS-3-agonistic compounds of formula I wherein A, A, A, R, R, R, Ar, Ar, Ar, m and n have the meanings given in the description, and also pharmaceutical compositions containing these compounds and a process for the preparation of compounds of Formula I are described.

Non-peptidic BRS-3 agonists

Method of treating or inhibiting obesity

Substituted &#x3b2;-lactones (oxetanones) corresponding to the formula I, wherein R, Rand n have the meanings given in the specification, and pharmaceutical compositions which contain these compounds and have a pancreatic lipase-inhibiting action, as well as a process for the preparation of the compounds of Formula I and intermediate products of this process.

Alkyl carbamate-substituted &#x3b2;-lactones, process for their preparation, and pharmaceutical compositions containing them

Method of identifying compounds suitable for treatment and/or prophylaxis of obesity

Novel and known trifluoroacetyl-substituted phenyl, phenol and benzoyl compounds for the treatment and/or inhibition of obesity and of concomitant and/or secondary diseases involved therewith, in particular metabolic syndrome and cardiovascular diseases. Novel trifluoroacetyl-substituted phenyl, phenol and benzoyl compounds, pharmaceutical preparations containing them and processes for the preparation of these compounds. Also compounds acting as inhibitors of lipase, in particular pancreatic lipase.

Trifluoroacetylalkyl-substituted phenyl, phenol and benzoyl compounds and related methods of treatment

A method for stereochemically controlled production of azacyclic compounds of general formula (I)in which the substituents have the meanings given in the specification. The invention also relates to intermediate products of this method and to novel azacyclenes.

Method for stereochemically controlled production of isomerically pure highly substituted azacyclic compounds

1-&lsqb;1-(hetero)aryl-1-perhydroxyalkylmethyl&rsqb;-piperazine compounds, process for their preparation and pharmaceutical compositions containing them

Neurokinin-antagonistic compounds corresponding to formula I: ##STR1## in which R.sup.1 is hydrogen or lower alkyl,

7-phenyl-1, 4-diazepane compounds, process for their preparation, and

Growing community of inventors

Bad Muender, Germany

Jochen Antel